Abstract 47P
Background
Compared with other breast cancer subtypes, TNBC is characterised by higher tumour mutational burden, elevated levels of PD-L1 expression and increased levels of immune cell infiltration. Predictors of immunotherapy response are not yet fully elucidated with several responders harbouring both PD-L1- and TMB-low tumours. We investigated the clinical and molecular traits associated with PD-L1 expression in TNBC patients with the aim to uncover distinct signatures that may impact on PD-L1 status and could potentially explain divergent responses to ICIs.
Methods
We performed WES, RNAseq and IHC using FFPE blocks from primary tumour resections derived from 196 treatment-naïve TNBC patients. Slides were stained with the anti- PD-L1 clone 22C3 and scored using a cut-off of CPS>=10 for PD-L1-high samples. DGE analysis was conducted between PD-L1-high and -low cases. The read count matrix was normalized using the median of ratios via DESeq2. A generalized linear model identified DEGs, followed by pathway analysis using over-representation analysis with KEGG pathways. Additionally, GSEA was employed to evaluate specific gene sets within the expression data.
Results
Almost one fourth of TNBC patients were PD-L1-high. The most frequent mutations in both groups involved TP53, PIK3CA, BRCA1, RB1 and PTEN genes with PIK3CA mutations almost exclusively encountered in PD-L1-high tumours. In PD-L1-high tumours, most DEGs (n=1708) were downregulated, including cell adhesion and collagen-related genes, while the up-regulated genes (n=481) included HLA isotypes, IFN-gamma, JAK2 and STAT1. Most DEGs were involved in the neuroactive ligand-receptor interactions, calcium, cAMP and cell adhesion signalling pathways. Immune, chemokine and JAK-STAT signalling pathways were positively enriched in PD-L1-high tumours.
Conclusions
This integrative analysis of clinical, genetic, transcriptomic and immunohistochemical data revealed differences in mutational signatures and gene expression patterns between PD-L1-high and -low TNBC tumours.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
A. Semertzidou, O. Arqués, Z. Lai: A.E. Storti, M. Heininen-Brown, S. Willis, B. Nuttall, M. Scaltriti, R. Stewart: Financial Interests, Institutional, Full or part-time Employment: AstraZeneca. S. Hassanieh, E.M. Wigmore: Financial Interests, Institutional, Full or part-time Employment, Shareholder: AstraZeneca. E. De Bruin: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. H. Angell: Financial Interests, Institutional, Advisory Board: AstraZeneca.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract